Cogentix Medical
→
Laborie Medical Technologies
Acquisition · Cash · announced Mar 12, 2018
Announced
Mar 12, 2018
Closed
Apr 23, 2018
Economics
Cash()
Pre-deal · pre-deal mark: 2018, year precision · Laborie Medical Technologies press release — Cogentix acquisition, 2019
$3.85/share, ~$214M enterprise value
Target
Cogentix Medical
Pelvic Health · Clinical / therapeutic
HQ Minnetonka, MN · Founded 1997
Urogynecology devices — Urgent PC neuromodulation (percutaneous tibial nerve stimulation for overactive bladder) and PrimeSight cystoscopy with EndoSheath protective barrier
- SEC EDGAR — Cogentix Medical merger filing (Mar 12, 2018)
- Laborie Medical press release (Apr 23, 2019 — completion)
Acquirer
Laborie Medical Technologies
Pelvic Health
HQ Mississauga, Canada
Why this buyer
Curated copy from the verified dataset — not an 8-K LLM summary
Urgent PC neuromodulation and PrimeSight cystoscopy expand Laborie's urology/urogynecology portfolio — addresses overactive bladder and stress urinary incontinence
Evidence ladder
Primary (regulatory / filing)
SEC EDGAR — Cogentix Medical merger filing (Mar 12, 2018)
Tertiary (trade / analyst)
Laborie completion (Apr 23, 2018)
Primary (regulatory / filing)
SEC EDGAR 8-K (Cogentix, Mar 12, 2018 — merger agreement) https://www.sec.gov/Archives/edgar/data/894237/000114036118013088/form8k.htm
Open sourcePrimary (regulatory / filing)
SEC EDGAR 8-K (Cogentix, Apr 24, 2018 — merger consummated Apr 23, 2018) https://www.sec.gov/Archives/edgar/data/894237/000119312518127561/d569300d8k.htm
Open source
Limitations
- $3.85/share, ~$214M enterprise value
- Pre-deal valuation sourced from: Laborie Medical Technologies press release — Cogentix acquisition, 2019. Pre-deal market-cap and funding citations do not corroborate the acquisition.
Valuation peers · Pelvic Health
Same sector, same deal type, announced within ±3 years, disclosed value within 0.25×–4× of this transaction. Ranked by evidence class, then same acquirer, until you sort.
| Why included | ||||
|---|---|---|---|---|
| Nine Continents Medical | Coloplast | Nov 3, 2020 | same evidence class |
Other verified deals by Laborie Medical Technologies
Acquirer program history not already listed as a valuation peer or adjacency row.
No further verified deals
Other verified transactions by Laborie Medical Technologies are already listed above, or none are in the dataset.
Patient empowerment context
Patient empowerment baseline (HLTH 2022)
No curated mapping — Cogentix Medical (Pelvic Health). HLTH/Outcomes4Me 2022 baseline is Breast cancer care continuum (HLTH 2022). No curated mapping for this target in the verified crosswalk.
Research workspace (includes heuristic crosswalk) →Related verified workspaces
Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.
Curated verified dataset v11 · updated 2026-10-19 · 4 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.